BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

RuiYi (formerly Anaphore) and arGEN-X Announce Exclusive Worldwide License Agreement for ARGX-109, a Novel Anti-IL-6 Antibody


10/4/2012 6:33:21 AM

LA JOLLA, Calif., BREDA, Netherlands and GHENT, Belgium, Oct. 4, 2012 /PRNewswire/ -- RuiYi (formerly Anaphore) and arGEN-X BV announced today that arGEN-X has granted a worldwide exclusive license to RuiYi to develop and commercialize ARGX-109, a novel anti-IL-6 monoclonal antibody discovered and developed by arGEN-X.

Under the agreement, RuiYi will make an upfront payment to arGEN-X consisting of cash and equity. arGEN-X is also eligible to receive additional payments based on the achievement of certain clinical, regulatory and commercialization milestones and royalties based on worldwide net sales of therapeutic products.

"The arGEN-X SIMPLE Antibody technology enables novel antibodies with outstanding features of potency, human composition and manufacturability," said Paul Grayson, President and CEO of RuiYi. "ARGX-109 was carefully selected based on its physical and biologic attributes and its range of potential clinical applications in both inflammatory diseases as well as oncology indications. Furthermore, the addition of this molecule accelerates our growth as an early development stage company in China."

"We are excited to partner our first preclinical program so early in our lifetime as a therapeutic antibody company," added Tim Van Hauwermeiren, Chief Executive Officer of arGEN-X. "We believe RuiYi's development strategy of first developing ARGX-109 in China is a highly innovative approach to drug development and will maximize the clinical and commercial potential of ARGX-109."

About ARGX-109

ARGX-109 is the first of five preclinical stage human antibody candidates developed by arGEN-X from its SIMPLE Antibody platform in the three years since its start of operations. ARGX-109 has outstanding neutralization potency for IL-6, a cytokine widely implicated in cancer and autoimmunity.

About RuiYi

RuiYi is focused on the discovery and development of novel biologic therapies in China, including monoclonal antibodies that target G protein coupled receptors (GPCRs). RuiYi's executive management team has offices in La Jolla, California while all of RuiYi's discovery efforts are located in Shanghai, China. RuiYi's research facility is located in the Zhangjiang Hi-Tech Park in Pudong Shanghai, China.

For more information please visit www.ruiyibio.com.

About arGEN-X

arGEN-X is a preclinical stage biopharmaceutical company that is rapidly leveraging its powerful, proprietary SIMPLE Antibody platform to generate fully human antibodies with differentiated qualities and outstanding therapeutic potential. The platform excels in delivering large panels of ultra-potent, functionally diverse antibodies against complex disease targets, especially cell surface receptors and highly conserved proteins. The superior choice that arGEN-X brings to antibody discovery enables it to prioritize leads with best-in-class therapeutic properties to increase the probability of development success. SIMPLE Antibody leads have outstanding physicochemical properties and consistent manufacturability, enabling a seamless transition from discovery into development. arGEN-X has validated its technology on multiple diverse classes of targets to date and has successfully delivered in its collaboration with Eli Lilly & Co. Earlier this year, arGEN-X entered into a second strategic alliance with Shire, focused on the discovery and development of antibody therapeutics for rare diseases.

As a complement to its SIMPLE Antibody platform and to maximize therapeutic utility, arGEN-X is also applying NHance and Potelligent® technologies, in partnership and for its proprietary pipeline.

SIMPLE Antibody and NHance platforms are covered by broad patent claims, enjoy an independent, unencumbered patent position and are free of target gatekeeping restrictions. SIMPLE stands for Superior Immunodiversity with Minimal Protein Lead Engineering. arGEN-X, SIMPLE Antibody and NHance are deposited trademarks of arGEN-X BV. Potelligent® is a deposited trademark of BioWa Inc.

For more information please visit www.arGEN-X.com

SOURCE RuiYi



Read at BioSpace.com
Read at ChinaBio Today

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->